Derazantinib and Atezolizumab in Patients With Urothelial Cancer
Public ClinicalTrials.gov record NCT04045613. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR Aberrations
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to evaluate efficacy of derazantinib monotherapy or derazantinib-atezolizumab in combination in patients with advanced urothelial cancer harboring fibroblast growth factor receptor (FGFR) genetic aberrations (GA) of various clinical stages of disease progression and prior treatments.
Study identification
- NCT ID
- NCT04045613
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 95 participants
Conditions and interventions
Conditions
Interventions
- Derazantinib 300 mg once daily monotherapy Drug
- Derazantinib 200 mg once daily + atezolizumab 1200 mg Drug
- Derazantinib 300 mg once daily + atezolizumab 1200 mg Drug
- Derazantinib 200 mg twice daily + atezolizumab 1200 mg Drug
- Derazantinib 300 mg once daily monotherapy (QD) Drug
- Derazantinib 200 mg twice daily monotherapy Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2, 2019 (Actual)
- Primary completion
- Oct 4, 2022 (Actual)
- Completion
- Oct 4, 2022 (Actual)
- Last update posted
- Oct 13, 2023
2019 – 2022
United States locations
- U.S. sites
- 7
- U.S. states
- 4
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CTCA Clinical Research Inc., Atlanta | Newnan | Georgia | 30265 | — |
| Englander Institute Weill Cornell Medicine | New York | New York | 10021 | — |
| New York Cancer and Blood Specialists | Port Jefferson Station | New York | 11776 | — |
| University of Texas Southwestern Medical Center (UTSWMC) | Dallas | Texas | 75390-8852 | — |
| MD Anderson | Houston | Texas | 77030 | — |
| NEXT Oncology | San Antonio | Texas | 78229 | — |
| Medical Oncology Associates PS (dba Summit Cancer Centers) | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 59 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04045613, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04045613 live on ClinicalTrials.gov.